levodopa improved formulation / Orion Corp - LARVOL DELTA

Real-world considerations of the use of Stalevo in Parkinson's Disease. (PubMed, Eur J Neurol) - "Experience with LCE has established that improved levodopa pharmacokinetics achieved with dual-enzyme inhibition are translated into improved clinical efficacy, including the possibility of reducing total levodopa dosage with no loss of therapeutic effect. The hepatotoxicity observed with the class comparator tolcapone has not been observed with entacapone, the COMT inhibitor in LCE, and there is no formal requirement to monitor liver function during LCE therapy. Other common side effects include diarrhoea, which is one of the more prominent non-dopaminergic adverse events, and urine discolouration, which is harmless but about which patients may require reassurance."

Journal • Real-world • Real-world evidence • Review • CNS Disorders • Hepatology • Movement Disorders • Parkinson's Disease

Pharmacokinetic of Levodopa Study in Healthy Males (clinicaltrials.gov) - P1; N=20; Completed; Sponsor: Orion Corporation, Orion Pharma; Active, not recruiting ➔ Completed

Trial completion • Biosimilar • CNS Disorders • Gene Therapies • Parkinson's Disease

COMDOS1: Dose-finding Pharmacokinetic Study in Healthy Males (clinicaltrials.gov) - P1; N=56; Completed; Sponsor: Orion Corporation, Orion Pharma; Recruiting ➔ Completed

Trial completion • Biosimilar

NOCOFPK2-Pharmacokinetic Study in Healthy Volunteers (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Orion Corporation, Orion Pharma

New P1 trial • Biosimilar • Parkinson's Disease